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Background. In the frame of a nationwide study of 
oropharyngeal carcinoma in the Netherlands (1986- 
1990), the current International Union Against Cancer 
1992/American Joint Committee on Cancer 1988 staging 
system was evaluated with respect to patient distribution 
and prognostic value.
Methods. Data related to epidemiology, treatment 
and survival from 640 patients referred for primary treat­
ment were analyzed. Staging was first evaluated in a pro- 
portional-hazard regression analysis controlled for these 
data. Next, all possible combinations of T, N, and M were 
tested in a stepwise backward elimination model until all 
remaining indicator variables had a P value of less than 
0.05. New stages were defined, based on the coefficients of 
the remaining indicator variables.
Results. The revised stages revealed two advantages
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compared with the UICC1992/AJCC1988 version: a more 
balanced distribution of patients (31% in Stage I, 31% in 
Stage II, 18% in Stage III, 14% in Stage IV, and 5% un­
known in the revised staging system versus 7% in Stage I, 
17% in Stage II, 24% in Stage III, 50% in Stage IV, and 2% 
unknown in the UICC 1992/AJCC 1988 staging system), 
and an improved prognostic discrimination for the dis­
ease specific survival (5-year results in the revised stag­
ing were 67% in Stage 1,42% in Stage II, 28% in Stage III, 
and 11% in Stage IV, versus 68% in Stage I, 64% in Stage
II, 44% in Stage III and 27% in Stage IV in UICC 1992/ 
AJCC 1988).
Conclusion. Improvements in the current staging 
system in patient distribution in the stages in prognostic 
discrimination is feasible by regrouping the T, N, and M 
but without redefining the categories themselves. Cancer 
1995;75:2656-62.
Key words: oropharyngeal carcinoma, staging, patient 
distribution, disease specific survival, prognostic factors.
The results of diagnostic procedures in oncology are 
usually defined in terms of three tumor characteristics: 
T (size and extent of the primary tumor), N (size and 
extent of the regional metastasis), and M (evidence or 
absence of distant metastasis), each characteristic hav­
ing a number of possible values. The purpose of this 
classification system is to provide a standard means of 
communication concerning individual patients or 
groups of patients. The T, N, and M can further be com­
bined into three or four stages, each encompassing a 
population that is, ideally, homogenous with respect to 
prognosis under specified treatment strategies. For indi-
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Table 1. TNM Classification and Stage Grouping 
According to the International Union Against Cancer 
’92/American Joint Committee on Cancer *88 System
T1 < 2  cm
T2 2-4 cm
T3 >4 cm
T4 Extension to bone, muscle, skin, neck, etc.
NO No evidence of lymph node metastasis
N1 Single ipsilateral metastasis <3 cm
N2a Single ipsilateral metastasis 3-6 cm
N2b Multiple ipsilateral metastasis < 6  cm
N2c Bi- or contralateral metastasis < 6  cm
N3 Metastasis ^6 cm
M0 No evidence of distant metastasis
Ml Distant metastasis
Stage grouping
I T1 NO MO
II T2 NO MO
III T3 NO MO, Tl-3 N1 M0
IV T4 N0-1 M0, any T N2-3 M0, any T any N M l
vidual patients, staging should direct the choice of ther­
apy and predict its success. In clinical studies, stage 
grouping should enable comparison of patient popula­
tions with the same tumor with respect to the results of 
different treatment modalities. The most widely used 
TNM classification for oropharyngeal carcinoma and 
stage grouping, the latter being common for all head 
and neck carcinomas, is shown in Table l .1
In oropharyngeal carcinoma, at least 70% of pa­
tients present with advanced disease (Stages III—IV); 
more than half of the patients present with Stage IV 
disease.2-5 Due to the low incidence of this tumor (0.3- 
0.5% of all malignancies),4,6 few patients have Stages I-
II at all. Stages III and IV, on the contrary, are large but 
heterogeneous. A more balanced distribution over the 
stages, leading to relative enlargement of Stages I and II 
and increased coherence of Stages III and, particularly,
IV, might add practical value to the current stage group­
ing. Ideally, this should be obtained through redefining 
of each stage with respect to T, N, and M, which by 
themselves remain unchanged. Moreover, the stage 
grouping should have a stronger prognostic significance 
than the separate categories included.
In the frame of the nationwide study on oropha­
ryngeal carcinoma in the Netherlands from 1986 until 
1990 conducted by the Dutch Head and Neck Oncology 
Cooperative Group, data related to epidemiology, treat­
ment, and survival of 640 patients were collected/ Cur­
rent staging for this large patient population was criti­
cally assessed and revised.
Materials and Methods
The study was conducted in seven leading centers that 
participate in the Dutch Head and Neck Oncology Co­
operative Group: the University Hospitals of Gron­
ingen, Leiden, and Maastricht in combination with the 
Radiotherapeutic Institute, Limburg; Nijmegen and 
Rotterdam in combination with the Dr. Daniel Den 
Hoed Cancer Centre, Utrecht; and the Netherlands 
Cancer Institute in combination with the University of 
Amsterdam. In each center, records of patients admit­
ted for oropharyngeal carcinoma between 1986 and 
1990 were reviewed. Data management was performed 
at the Comprehensive Cancer Centre, Amsterdam. 
Other details related to the organization of the study, 
data collection, and management were reported ear­
lier.7
Patients
Six hundred forty patients who were admitted for pri­
mary treatment of histologically proven squamous cell 
carcinoma or undifferentiated carcinoma of the oro­
pharynx were analyzed. Four hundred forty-one pa­
tients (69%) were males and 199 (31%) females, with a 
median age of 59 years (range, 30-92 years).
Staging
Staging was done according to the 1992 rules of the In­
ternational Union Against Cancer (UICC),1 which are 
in accordance with those of the American Joint Com­
mittee on Cancer (AJCC), as proposed in 19888 (Table
1). Distribution by T and N is shown in Table 2. Distant 
metastases were present in 9 patients (1%), absent in 
602 patients (94%), and unknown in 29 patients (5%). 
Distribution by stage according to the UICC 1992 clas­
sification, shown in Figure 1, was as follows: 44 patients 
(7%), Stage I; 106 (17%), Stage II; 157 (24%), Stage III; 
319 (50%), Stage IV, and 14 (2%), unknown stage.
Vital Status and Survival
At the end of the follow-up, 225 patients (35%) were 
alive with no evidence of disease (NED), 17 (3%) were 
alive with tumor, 74 (12%) were dead with NED, 316 
(49%) were dead with tumor, and 8 (1%) were lost to 
follow-up. In surviving patients, median follow-up was 
at 3 and 6 years, and maximal follow-up was at 7 years. 
When split up by center, tumor status at death appeared 
to range from 7-27% of patients having NED, but these 
differences were likely to have been caused by chance 
(P = 0.35).
Definitions and Statistical Analysis
Patients were followed up for at least 3 years or until 
death. Survival was defined as the time between the
Table 2. International Union Against Cancer ’92 Distribution by T, N, and M* and by Stage
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T1 no. (%) T2 no. (%) T3 no. (%) T4 no. (%) Unknown no, (%) Total no. (%)
NO 48 (7) 110(17) 63 (10) 37(6) - 258 (40)
N 1 14(2) 33(5) 53(8) 48(8) 3(<1) 151 (24)
N2 1 1 (2) 47(7) 63 (3) 61(9) - 182(28)
N3 6 (1 ) 7(1) 17(3) 16(2) - 46(7)
Unknown - - - 3 ( d ) - 3(<1)
Total 79(12) 197(31) 196 (31) 165 (26) 3 «1 ) 640(100)
Stage I 44(7)
Stage II 106(17)
Stage III 157(24)
Stage IV 319(50)
Stage unknown 14(2)
date of diagnosis and the end of follow-up or death. For 
the disease specific survival, only those patients who
of prognostic factors)/ these dummy variables were 
added to the model, until no one had a P value of the
Results
died of oropharyngeal tumor (local, regional, and/or size indicated/ thereby recombining the T, N, and M 
distant) were considered dead. Survival curves were categories into a new staging, 
calculated using the life-table method.
Univariate analyses were performed with the log rank 
statistic. Cox's proportional hazards model was used for 
multivariate analyses. In the main analysis of stage, we 
controlled for all variables, as listed in Table 3.
These data were available for 594 patients* Treat­
ment modality was used to define strata, and all other 
variables were used as covariates. To find an optimal 
combination of T, N, and M categories, we created 
dummy variables (0 or 1) indicating whether a patient 
had a T (or N) category larger than a particular value 
and also all possible products of these dummy variables 
for T, N, and M resulting in a total of 4 X 6 X 2  — 1 =
47 dummy variables. However, because not all possible 
combinations of T, N, and M existed, four had to be 
deleted. Then, in a stepwise manner (with P values of 
0.15 to enter and remove, as standardly used in analysis Revised Staging
The overall survival at 5 years was 28%. The 5-year 
disease specific survival was 41%; 35% in males and 
51% in females (P = 0.003); in soft palate/uvula, 
54%; tonsillar region, 42%; base of the tongue, 33%; 
and in posterior oropharyngeal wall, 32% (P = 0.003); 
Stage I (UICC, 1992), 68%; II, 64%; III, 44%; and IV, 
27% (P < 0.0001) (Fig. 2); treatment by surgery alone, 
80%; surgery and radiotherapy, 51%; radiotherapy 
alone, 36%; other treatments, 7%; and no treatment, 
5% (P < 0.0001); 5-year disease specific survival 
ranged over the centers from 24% to 64% (P == 0.009).
patients
3 0 0 -
200-
100 -
0
319
157
106
44
14
IV unknown
stage
Figure 1. Distribution of the UICC 1992 staging system.
Controlled for the variables listed in Table 2, stage group- 
ing was still associated with survival (P < 0.0001). How­
ever, when additionally controlled for stage grouping, 
there is still some evidence that T category (test for linear 
In [hazard]; P = 0.028) as well as N category (P = 0.031) 
carry additional prognostic information.
In the stepwise procedure, which is used to find an 
optimal combination of T, N, and M categories, we 
chose to include M category (P = 0.035) regardless of its 
P value. Next, T3-4N1-3 (P < 0.0001), N3 (P = 0.0002), 
Nl-3 (P = 0.032), T3-4 (P = 0.015), and T4N1-3 (P = 
0.077) were included consecutively. Finally, T3-4N1-3 
(P = 0.36) was again removed.
At this stage, T4N3 had a P value of 0.031, and T2- 
4N3 had a P value of 0.13, but both had a negative log 
(relative hazard), indicating that the associated disease 
specific survival was better than expected on the basis
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Table 3. Variables Related to Treatment, Tumor, and Epidemiology Used in Cox's 
Proportional Hazard Method Analysis With Related Categories and Distribution 
of Patients
Variable No. Variable No.
Treatment Tumor (cont)
Modalities Side
surgery alone (42) left (269)
RT alone (408) right (298)
surgery and RT (147) midline (73)
other treatment (14) Histopathology
no treatment (29) squamous (628)
Neck dissection undifferentiated (1 2 )
radical (142) Referral
modified (58) primary tumor (627)
selective (17) otherwise, not recurrence§ (13)
none (423) Epidemiology
Type of surgery Center
combined resection (133) UH|| Groningen (70)
PT* and NNf in one session UH Leiden (43)
but discontinuous (17) UH Maastricht/RTILIi (70)
Resection of mandibula UH Nijmegen (93)
yes (55) UH Rotterdam/DDHCC# (2 1 2 )
no (135) UH Utrecht (75)
Bra chy therapy NKI*!f!/U H  Amsterdam (77)
yes (73) Incidence
no (567) 1986 (97)
Chemotherapy 1987 (133)
yes (54) 1988 (139)
no (584) 1989 (146)
Other treatments 1990 (125)
yes (14) Sex
no (626) men (441)
Standard protocol:): women (199)
yes (530) Age (yrs)
no (98) <50 (151)
rr*
lumor 50-59 (181)
Subsite 60-69 (175)
tonsillar region (372) &70 (133)
soft palate/uvula (62)
base of the tongue (179)
posterior wall (27)
* Primary tumor, 
f Neck nodes.
$ Treatment according to the existing standard protocol in the different institutes.
§ Patient seen for second opinion and subsequently primarily treated in the "second opinion institute." 
| University hospital.
Tf Radiotherapeutic Institute Limburg.
# Dr. Daniel Den Hoed Cancer Centre.
** The Netherlands Cancer Institute.
of the variables already in the model. Therefore, these 
variables were not included. The final result gives the 
following optimal score function:
1.28*M1 + 0.64*T3~4 + 0.45*N2~3 + 0.67*N3
+ 0.39*T4Nl-3.
The associated standard errors in the same order 
are 0.48, 0.16, 0.15, 0.22 and 0.17, respectively, with 
P values at this stage of 0.018, <0.0001, 0.0024, 
0.0041, and 0.023. On the basis of this score function, 
T, N and M were recombined into stages as shown in 
Table 4.
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Table 4, Revised Staging
Stage I T 1-2 N 0 - 1
Stage II T 1-2 N 2
T 3 N 0 - 1
T 4 NO
Stage III T 1 - 2 N 3
T 3 N 2
T 4 N 1
Stage IV T 3 N 3
T 4 N 2-3
any T any N
MO
MO
MO
MO
MO
MO
MO
MO
MO
M l
T, N and M are identical as in the International Union Against Cancer '92/'92 
system.
Figure 2. Disease specific survival according to the UICC 1992 
stages.
Effects of the Revised Staging on Patient Distribution 
and Disease Specific Survival
crease was observed (P = 0.051). However, a much 
more impressive change emerged after controlling for 
the revised staging (P = 0.08) and midline origin in ad­
dition (P = 0.17).
Apart from stage, for midline origin (P < 0.0001) 
and sex (P < 0.02), there was persistent evidence for 
prognostic significance throughout all analyses. For age, 
this was only the case without controlling for treatment
When applied to our patient population, the revised modalities (P — 0.006); controlling for this variable, the
staging resulted in the following distribution: Stage I, P value for age increased to 0,08,
197 patients (31%); Stage II, 200 (31%); Stage III, 118 
(18%); Stage IV, 92 (14%); and unknown stage, 33 Discussion 
(5%). Compared with the UICC 1992 staging, reloca­
tion of patients toward lower stages is observed. It is The advantages of a more balanced distribution of pa- 
noteworthy that revised Stage IV contains only 14% of tients over the stages are obvious: the larger the group,
patients (Fig. 3). A higher proportion of patients with 
unknown stage in the revised system is caused by the 
fact that less patients with unknown M categories could 
be assigned to Stage IV on the basis of T and N catego­
ries alone.
the more powerful the statistical analyses based on that 
group can be. As stated in the introduction, the function 
of staging in directing the choice of therapy may gain 
practical value with increased Stages I and II, being the 
favorable groups, and decreasing Stages III and IV into
Figure 4 shows the disease specific survival of the the really unfavorable cases. This seems to be of great
revised stages, which is superior in prognostic discrimi­
nation to the UICC 1992 system (Fig. 2) in the case of 
this sample. The 5-year results with the revised system 
were 67% in Stage I, 42% in Stage II, 28% in Stage III, 
and 11% in Stage IV (P < 0.0001). With the revised stag­
ing, a more pronounced difference between Stages I 
and II (25% vs. 4% in UICC 1992) seems to have been 
achieved, so that a small group of patients with an ex­
tremely poor prognosis corresponding to Stage IV might 
have been identified.
patients
300
200-
Revised Staging and Other Prognostic Factors
Univariately, there was strong evidence of a different 
prognosis between the centers (P = 0,009), After con­
trolling for sex, age, and stage UICC 1992, the differ­
ence decreased to some extent (P = 0.015); when con­
trolling additionally for midline origin, a further de-
100
197 200
118
IV unknown
stage
Figure 3. Distribution by the revised staging system.
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Figure 4. Disease specific survival according to the revised stages.
UICC TANIS
since 1978.18 Of the recently published proposals for 
improving the UICC 1992/AJCC 1988 system, only a 
few papers proposed the easy-to-implement regroup­
ing of existing categories.10'15
Recently, two other interesting propositions have 
been published concerning a revision of the staging in 
head and neck cancer. Jones et al. proposed the addition 
of the values for T and N into an integer score, while 
leaving the M category out: this is called the TANIS (tu­
mor and nodes integer score) classification and leads to 
seven possible categories,10 Furthermore, they propose 
a stage grouping into three stages, Stage I comprising 
TANIS 1-3, Stage II comprising TANIS 4, and Stage 
III comprising TANIS 5-7. The TANIS classification is 
advantageous in that it is easy to apply and recall. When 
applied to our patient material, Stage I would have in­
cluded 267 patients; Stage II, 135; and Stage III, 205. 
Berg's classification method,15 like our series, which was 
also specifically applied to oropharyngeal cancer, is 
comparable to that of the UICC and the one proposed 
importance, because in many clinical trials (e.g., organ here because, it includes the M category and results in 
preservation studies9), all Stage III and IV patients are four stages. When applied to our patient population, the 
considered eligible candidates, and with the present 
staging system, this leads to heterogeneous groups of 
favorable and unfavorable patients. Stage IV, espe­
cially, should encompass only those patients with a 
poor prognosis. In our study, increased discrimination 
between revised stages suggests that such an improve­
ment may have been obtained. However, it should be 
noted that our regrouping is optimized for the sample 
studied here. Therefore, it is to be expected that an ap­
plication of this revised system to another group of pa­
tients would result in less diverging curves than shown 
in Figure 4. A study to get an independent evaluation of 
our stage system would be worthwhile, However, the 
fact that the original stage grouping can be improved on 
does not follow so much from a comparison of Figure 2 
and Figure 4, but from our finding that T and N catego­
ries as such carry prognostic information in addition to 
that of the UICC 1992 stage grouping.
Classification and staging systems in head and neck 
cancer are regularly evaluated and are being proposed 
for revisions.1,10"16 Globally, two types of revisions can 
be distinguished: those affecting definitions of T, N, 
and/or M that may require changes in diagnostic pro­
cedures and clinical routine handlings, thus complex in 
practical implementation, and those limited to regroup­
ing the existing categories, thereby affecting only ad­
ministrative aspects of staging. In the update of the 
TNM classification by UICC in 1987, new definitions of 
the N category were introduced.16 The latest update 
from 1992,1 commented on in 1993,17 did not involve 
oropharyngeal carcinoma. Stage grouping for head and 
neck carcinomas, however, has remained unchanged
N0 N1 n 2 n 3 N0 N l n2 n3
T1 I T1 I II
t 2 II
Mq
t2 II
t3 hi T3 II
T4 IV T4 II III
M0
any N any N
any T IV Mi anyT IV(?) Mi
BERG revised staging
N0 Ni n 2 n 3
T1 I M
t2 II
t3 III
T4 IVA
M0
N0 ^ n 2 N3
T*
'1
T2
I II III
II III
t 4
I Ml IV
M0
any N any N
any T IV B Mi anyT IV M-i
Figure 5, Diagramatic comparison of the stage grouping of the four 
different classification systems discussed (UICC 1992, TANIS, Berg, 
and the current revised staging).
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distribution over the stages would have been as follows: 
Stage 158; Stage II, 150; Stage III, 260; and Stage IV, 148 
patients. Figure 5 shows diagrammatically the different 
stage groupings discussed here.
Both the TANIS and the Berg systems improve on 
the stage grouping of the UICC in our material with re­
spect to prognostic power. The TANIS classification 
seems to be comparable in this respect with the re­
grouping proposed here, whereas there is some indica­
tion that Berg's staging is still somewhat inferior. With 
respect to the distribution of patients over stages, both 
are better than the UICC staging, but, as can be seen 
from the figures given above, are less balanced com­
pared with the regrouping proposed here. However, a 
more formal comparison between the four stage group­
ing systems, performed on independent material, 
would provide a better evaluation of these systems.
From our study, one can conclude that it is possible 
to improve the stage grouping of the UICC, leading to a 
more balanced distribution of patients over the stages 
and to better discrimination of distinct prognostic 
groups. Because there is ample evidence that the latest 
redefinitions of the T and N categories in the UICC and 
the AJCC classification systems have been real im­
provements, a comparable refinement of the stage 
grouping is long overdue.
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